Insights Home Insights Featured Content In the News Will the FTC’s Amgen Suit Ignite Future Pharmaceutical M&A Conflicts? With M&A activity in the life sciences sector heating up, the latest dispute in the space may affect the future of pharmaceutical acquisitions. How will the FTC's recent case against Amgen ignite future M&A conflicts, and where can experts assist in the litigation process? Article What’s Next for Microsoft and Activision’s Antitrust Battle After EU and UK Decisions The biggest gaming deal in history has hit another regulatory roadblock. As Microsoft continues to seek government approval for their acquisition of Activision, regulators in the UK and EU have announced conflicting opinions on the deal, creating a confusion about what’s to come for the merger. Article Expert Assessment: How the Crypto Crackdown Could Propel Conflict As crypto market players continue looking for concrete guidance regarding industry regulations, how will regulators respond to their requests for action? Read fintech expert Dr. Peter Vinella's insights on what he thinks is next for those in the digital assets space. Article Retaining Experts for Three Top Trends in Life Sciences in 2023 What are three growing trends in life sciences with legal implications, their drivers, and the types of experts that would be advantageous to retain? Learn more. Other Content White Paper: Theft of Trade Secrets in the Automotive Industry We take a close look at how the EV revolution is igniting an increase in trade secrets disputes and a call for top experts. Insights & News All Practice Areas Pharmaceutical Healthcare Technology Biotechnology Sexual Misconduct & Harassment Wireless Communications Video Gaming Financial Technology Automotive Complex Commercial Life Sciences Intellectual Property Energy & Natural Resources Employment Crisis Management All Trends 2023 Banking Crisis Lab-Grown Foods Wearable Devices Cryptocurrency FDA-Regulated Drugs and Devices Payment Systems Virtual Reality Electric Vehicles Election Law and Voting Rights 5G / 6G Drug and Vaccine Development COVID-19 All Insight Types Archive Article Blog Case Study Event In the News Other Content Press Release Video Search May 24, 2023 — In the News Will the FTC’s Amgen Suit Ignite Future Pharmaceutical M&A Conflicts? With M&A activity in the life sciences sector heating up, the latest dispute in the space may affect the future of pharmaceutical acquisitions. How will the FTC's recent case against Amgen ignite future M&A conflicts, and where can experts assist in the litigation process? May 17, 2023 — Article Retaining Experts for Three Top Trends in Life Sciences in 2023 What are three growing trends in life sciences with legal implications, their drivers, and the types of experts that would be advantageous to retain? Learn more. April 17, 2023 — Event ACI’s 18th Annual Paragraph IV Disputes Conference WIT Legal will sponsor lanyards and the day one luncheon at ACI's 18th Annual Paragraph IV Disputes Conference on April 19 and 20, 2023. April 4, 2023 — Press Release WIT Legal Expands Life Sciences Practice to Address Increase in Litigation Targeting Pharmaceutical, Biotechnology, and Healthcare Technology Companies The company has a reputation for building diverse teams of leading experts across trending areas of litigation and is committed to affiliating with the most qualified experts in emerging markets. March 21, 2023 — In the News QUICK LOOK: What’s Next for Opioid Litigation? While opioid litigation has already crossed a wide swath of drugmakers, distributors, and dispensers, plaintiffs’ attorneys aren’t done yet and have set their sights on a new crop of defendants. Defense teams should assemble and mobilize experts to inform their legal strategies. March 15, 2023 — Blog Growing Concern Over PFAS Chemicals Drives Litigation and a Need for Experts to Help Defense Counsel Understand Its Impact Litigation concerning manmade chemicals known as PFAS (Per- and polyfluorinated alkyl substances) is set to intensify in 2023. What can defense counsel representing companies, manufacturers, and distributors of consumer products containing PFAS chemicals do to prepare for the likelihood of litigation? Consult with experts. February 22, 2023 — Blog Pharmaceutical Industry’s Drug Patent Cliffs Approach, Giving Rise to the Need for Highly Credentialed Experts Several patents from the pharmaceutical industry’s best-selling drugs are set to expire. As a result, competition intensifies with copycat drugs already in the works and counsel strategizing on protecting monetized IP. January 6, 2023 — Case Study Case Study: How an Epidemiology Expert Supported Our Client’s Claims of Infringement The plaintiff, an American tobacco manufacturing company, sued a competing tobacco product producer after alleging that they infringed upon three patents related to electronic heating and vaping products. September 21, 2021 — Press Release WIT Expert Witness Agency Sees a Growing Demand for Experts Across Practice Areas The agency sees a more than 50% increase in demand for experts in Life Sciences and Energy-related matters. August 19, 2021 — Case Study Case Study: Experts Needed for the National Prescription Opiate Litigation WIT was retained by several manufacturers, distributors, dispensers, and benefit managers to provide consulting and testifying experts to support the defendants in dozens of lawsuits across the United States. Load More Loading...
In the News Will the FTC’s Amgen Suit Ignite Future Pharmaceutical M&A Conflicts? With M&A activity in the life sciences sector heating up, the latest dispute in the space may affect the future of pharmaceutical acquisitions. How will the FTC's recent case against Amgen ignite future M&A conflicts, and where can experts assist in the litigation process?
Article What’s Next for Microsoft and Activision’s Antitrust Battle After EU and UK Decisions The biggest gaming deal in history has hit another regulatory roadblock. As Microsoft continues to seek government approval for their acquisition of Activision, regulators in the UK and EU have announced conflicting opinions on the deal, creating a confusion about what’s to come for the merger.
Article Expert Assessment: How the Crypto Crackdown Could Propel Conflict As crypto market players continue looking for concrete guidance regarding industry regulations, how will regulators respond to their requests for action? Read fintech expert Dr. Peter Vinella's insights on what he thinks is next for those in the digital assets space.
Article Retaining Experts for Three Top Trends in Life Sciences in 2023 What are three growing trends in life sciences with legal implications, their drivers, and the types of experts that would be advantageous to retain? Learn more.
Other Content White Paper: Theft of Trade Secrets in the Automotive Industry We take a close look at how the EV revolution is igniting an increase in trade secrets disputes and a call for top experts.
May 24, 2023 — In the News Will the FTC’s Amgen Suit Ignite Future Pharmaceutical M&A Conflicts? With M&A activity in the life sciences sector heating up, the latest dispute in the space may affect the future of pharmaceutical acquisitions. How will the FTC's recent case against Amgen ignite future M&A conflicts, and where can experts assist in the litigation process?
May 17, 2023 — Article Retaining Experts for Three Top Trends in Life Sciences in 2023 What are three growing trends in life sciences with legal implications, their drivers, and the types of experts that would be advantageous to retain? Learn more.
April 17, 2023 — Event ACI’s 18th Annual Paragraph IV Disputes Conference WIT Legal will sponsor lanyards and the day one luncheon at ACI's 18th Annual Paragraph IV Disputes Conference on April 19 and 20, 2023.
April 4, 2023 — Press Release WIT Legal Expands Life Sciences Practice to Address Increase in Litigation Targeting Pharmaceutical, Biotechnology, and Healthcare Technology Companies The company has a reputation for building diverse teams of leading experts across trending areas of litigation and is committed to affiliating with the most qualified experts in emerging markets.
March 21, 2023 — In the News QUICK LOOK: What’s Next for Opioid Litigation? While opioid litigation has already crossed a wide swath of drugmakers, distributors, and dispensers, plaintiffs’ attorneys aren’t done yet and have set their sights on a new crop of defendants. Defense teams should assemble and mobilize experts to inform their legal strategies.
March 15, 2023 — Blog Growing Concern Over PFAS Chemicals Drives Litigation and a Need for Experts to Help Defense Counsel Understand Its Impact Litigation concerning manmade chemicals known as PFAS (Per- and polyfluorinated alkyl substances) is set to intensify in 2023. What can defense counsel representing companies, manufacturers, and distributors of consumer products containing PFAS chemicals do to prepare for the likelihood of litigation? Consult with experts.
February 22, 2023 — Blog Pharmaceutical Industry’s Drug Patent Cliffs Approach, Giving Rise to the Need for Highly Credentialed Experts Several patents from the pharmaceutical industry’s best-selling drugs are set to expire. As a result, competition intensifies with copycat drugs already in the works and counsel strategizing on protecting monetized IP.
January 6, 2023 — Case Study Case Study: How an Epidemiology Expert Supported Our Client’s Claims of Infringement The plaintiff, an American tobacco manufacturing company, sued a competing tobacco product producer after alleging that they infringed upon three patents related to electronic heating and vaping products.
September 21, 2021 — Press Release WIT Expert Witness Agency Sees a Growing Demand for Experts Across Practice Areas The agency sees a more than 50% increase in demand for experts in Life Sciences and Energy-related matters.
August 19, 2021 — Case Study Case Study: Experts Needed for the National Prescription Opiate Litigation WIT was retained by several manufacturers, distributors, dispensers, and benefit managers to provide consulting and testifying experts to support the defendants in dozens of lawsuits across the United States.
